Publicacións en colaboración con investigadores/as de University of Erlangen-Nuremberg (24)

2024

  1. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

  2. Can gait patterns be explained by joint structure in people with and without radiographic knee osteoarthritis? Data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 53, Núm. 11, pp. 2409-2416

2023

  1. Exploring the differences between radiographic joint space width and MRI cartilage thickness changes using data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 52, Núm. 7, pp. 1339-1348

  2. Quantitative CT of the knee in the IMI-APPROACH osteoarthritis cohort: Association of bone mineral density with radiographic disease severity, meniscal coverage and meniscal extrusion

    Bone, Vol. 168

  3. Test–retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort

    Osteoarthritis and Cartilage, Vol. 31, Núm. 2, pp. 238-248

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Mitochondrial DNA haplogroups associated with MRI-detected structural damage in early knee osteoarthritis

    Osteoarthritis and Cartilage, Vol. 26, Núm. 11, pp. 1562-1569

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Translating patient reported outcome measures: Methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages

    Rheumatology (United Kingdom), Vol. 55, Núm. 6, pp. 1009-1016

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  2. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

    Journal of Rheumatology, Vol. 42, Núm. 3, pp. 479-488

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026

2012

  1. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

    Arthritis Research and Therapy, Vol. 14, Núm. 3

  2. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

  3. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2011

  1. Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: A study in Spanish and Italian populations and meta-analysis

    Arthritis and Rheumatism, Vol. 63, Núm. 7, pp. 1860-1865